Compare Gen Digital Inc. Common Stock (GEN) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gen Digital Inc. Common Stock vs Organon & Co. Common Stock — how do they compare? Gen Digital Inc. Common Stock trades at $23.7 (market cap $14.24B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Gen Digital Inc. Common Stock is far larger — about 3.9× Organon & Co. Common Stock's market cap, and Gen Digital Inc. Common Stock pays the higher dividend (2.1%). Which is the better fit depends on your goals — on Pluang, investors hold Gen Digital Inc. Common Stock for 6 Days and Organon & Co. Common Stock for 0 Days on average.
| GEN | OGN | |
|---|---|---|
Market Cap | $14.24B | $3.62B |
Volume | 6,202,699 | 2,892,999 |
Sector | Technology | Health |
52-Week High | $31.41 | $13.81 |
52-Week Low | $17.89 | $5.70 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $21.89B | $11.04B |
Dividend Yield | 2.1% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GEN Digital Inc. (GEN) trades at $23.81, up 1.97% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a P/E of 13.92, net income margin of 20.73%, and robust cash flow from operations of $1.22B in 2025. Recent news highlights include a takeover bid for GoDaddy and participation in investor conferences, reflecting strategic moves in the cybersecurity and digital services sector.
The outlook is mixed: analyst consensus targets $25.50 with a balanced buy/hold split, but technical indicators suggest near-term pressure. Key risks include high debt levels and integration challenges from acquisitions. Earnings growth and market expansion into AI services present opportunities, though volatility may persist amid competitive and macroeconomic headwinds.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gen Digital Inc. Common Stock
Gen Digital provides cybersecurity, online privacy, identity protection, and financial wellness services. Its consumer brands include Norton, Avast, LifeLock, and MoneyLion.
Read more on GEN →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
